Skip to main content
Premium Trial:

Request an Annual Quote

Tegal Gets Shareholder OK to Change Name to CollabRx

NEW YORK (GenomeWeb News) – Tegal said after the close of the market yesterday that it has received approval from its shareholders to change the name of the firm to CollabRx.

The name change comes a couple of months after Tegal completed its purchase of genomics data analysis firm CollabRx for an undisclosed amount. At the time, Tegal had said that it would ask its shareholders to approve the name change.

As of tomorrow, the firm's shares will trade on the Nasdaq under the ticker symbol CLRX.

Tegal develops new and emerging technologies with a current focus on technologies in the medical device and healthcare segments. CollabRx offers cloud-based systems to inform healthcare decision-making using genomics-based medicine.

Each firm's CEO — Thomas Mika of Tegal and James Karis of CollabRx — are serving as co-CEOs of the San Francisco-based firm. Mika continues to serve as chairman.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.